Featured

Gensco® Pharma Announces RizaFilm® Commercialization Update in the United States

Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch of RizaFilm® for Q1-2024. RizaFilm® is based on IntelGenx’s proprietary VersaFilm® technology and is patent protected until 2034. As the NDA holder, Gensco® will begin commercialization of the 10mg Film and will continue to fund the expanded indications for the 5mg Pediatric dose.

RizaFilm® is a film formulation of rizatriptan and the only oral dissolvable film available for the treatment of acute migraines. RizaFilm® has ease of convenience and does not require a drink for swallowing, thus allowing for rapid administration and relief from migraine related pain and nausea.

Now Available Through Federal Supply Schedule (FSS)

Now Available Through Federal Supply Schedule (FSS)

Contract #V797D-70219 The Only FDA-Approved Prescription Hydrogel and 4% Lidocaine HCl for Pain Associated with Wound Healing and Vasculitis FDA Approved #K092086 Astero®, manufactured by Gensco Pharma, is now available through the Federal Supply Schedule. Astero®...
Physician Explores Gout Treatment Options

Physician Explores Gout Treatment Options

As seen in Chain Drug Review | May 15, 2017 MIAMI — Gout is an extremely painful form of inflammatory arthritis and the most common form of this type of arthritis in men, according to Dr. Gary Myerson, a founding fellow of the American College of Rheumatology....
Advances in Treatment of Painful Wounds

Advances in Treatment of Painful Wounds

by Marc Alan Brenner, DPM, The Institute for Diabetic Foot Research As seen in Podiatry Management | November 2016 Wound management is one of the most common aspects of podiatric practice. The etiology of the wound may vary from post-surgical, traumatic, or disease...